Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
20
作者人数
1
被引次数
来源:Crossref,截至 2026-10-20
作者
- 1 Wenting Chen 第一作者
- 2 Jianhua You
- 3 Li’e Lin
- 4 Xiaojing Yan
- 5 Gang An
- 6 Yafei Wang
- 7 Weiwei Tian
- 8 Kaiyang Ding
- 9 Xi Zhang
- 10 Wenming Chen
首都医科大学附属北京朝阳医院
- 11 Yingxue Wang
- 12 Baijun Fang
- 13 Jing Liu
中南大学湘雅三医院
- 14 Weilin Xia
- 15 Zhaoyi Feng
- 16 Lei Zhou
- 17 Zhini Wang
- 18 Dan Shen
- 19 Gang Liu
- 20 Weili Zhao
参考文献 共 31 条
- 1 Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study 10.1038/leu.2011.196
- 2 Management of multiple myeloma in the newly diagnosed patient 10.1182/asheducation-2017.1.498
- 3 Current frontline treatment of multiple myeloma
- 4 Bortezomib-based regimens for newly diagnosed multiple myeloma in China: A report of 12-year real-world data 10.3389/fphar.2020.561601
- 5 Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China 10.1002/cam4.5234
- 6 The changing landscape of relapsed and/or refractory multiple myeloma (MM): Fundamentals and controversies 10.1186/s40364-021-00344-2
- 7 Management of multiple myeloma in the relapsed/refractory patient 10.1182/asheducation-2017.1.508
- 8 Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma 10.1016/j.clml.2022.01.011
- 9 Daratumumab: A review in relapsed and/or refractory multiple myeloma 10.1007/s40265-017-0837-7
- 10 Isatuximab: First approval 10.1007/s40265-020-01311-1
- 11 SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies 10.1158/1078-0432.ccr-14-0695
- 12 Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma 10.1158/1078-0432.ccr-16-3192
- 13 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study 10.1016/s0140-6736(19)32556-5
- 14 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study 10.1016/s1470-2045(22)00019-5
- 15 Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
- 16 Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in east asian patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis 10.1016/j.clml.2022.04.005
- 17 Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataset 10.1097/hs9.0000000000000738
- 18 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study 10.1111/ejh.14225
- 19 A Bayesian approach for inference from a bridging study with binary outcomes 10.1080/10543406.2012.698436
- 20 Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study 10.1186/s13045-017-0501-4
- 21 A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China 10.1007/s12185-020-03044-z
- 22 Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies 10.1002/sim.6607
- 23 Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial 10.1186/s12885-022-09802-y
- 24 Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: A multicenter, open-label, single-arm trial 10.1007/s00277-023-05558-y
- 25 Pomalidomide and dexamethasone are effective in relapsed or refractory multiple myeloma in a real-life setting: A multicenter retrospective study in Taiwan 10.3389/fonc.2021.695410
- 26 Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China 10.1002/cam4.7232
- 27 Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): Extended follow up of an open-label, randomised, multicentre, phase 3 trial 10.1016/s2352-3026(23)00218-1
- 28 Prevalence and incidence of multiple myeloma in urban area in China: A national population-based analysis 10.3389/fonc.2019.01513
- 29 Real-world Data on the efficacy and safety of ixazomib-based therapy in multiple myeloma: A single-center study in China 10.2147/cmar.s261887
- 30 The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China (in Chinese)
- 31 A retrospective study of the BiRd regimen in the treatment of relapsed/ refractory multiple myeloma (in Chinese)
数据来源
- 论文信息:
- 中华医学期刊网、Crossref
- 作者名单:
- Crossref
- 被引次数:
- Crossref,截至 2026-10-20
- 参考文献:
- Crossref
论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。